Opportunity Information: Apply for RFA CK 20 002
The grant opportunity "Detection and Characterization of Emerging Vector-Borne and Zoonotic Pathogens in Indonesia" (Funding Opportunity Number RFA CK 20 002) is a CDC-led cooperative agreement meant to strengthen Indonesia's ability to rapidly detect, correctly identify, and better characterize emerging diseases that spread through vectors (like mosquitoes, ticks, and fleas) or from animals to humans. The central aim is to build directly on laboratory capacity, surveillance systems, and scientific partnerships that CDC and Indonesian institutions have already established under earlier awards, rather than starting from scratch. The focus is on practical, real-time public health impact: making sure that when unusual febrile illnesses or suspected outbreaks appear, the country has reliable systems to recognize what pathogen is responsible and respond before it spreads widely.
A major reason this opportunity exists is Indonesia's unusually high risk profile for emerging infectious diseases. Indonesia is often described as a global hotspot because it has a very large population distributed across almost 1,000 inhabited islands over a long equatorial span. That geography creates constant movement of people, animals, and goods across many ecological zones, which increases the chance that a new pathogen can emerge locally and then spread regionally or internationally. In a setting like that, gaps in diagnostic coverage and surveillance can allow outbreaks to grow unnoticed, especially when early symptoms look like common acute febrile illness.
The NOFO highlights two specific pathogen groups as priorities: arboviruses and Rickettsia. Arboviruses are transmitted by arthropods and can move efficiently between wildlife, livestock, and humans, making them hard to control once established. Rickettsial diseases (including typhus group and spotted fever group illnesses) are also emphasized because they can cause severe disease but are easily missed clinically and require targeted diagnostics. The opportunity points out a striking knowledge gap in Indonesia, noting that relatively few pathogenic arboviruses have been documented there compared with neighboring Australia, suggesting under-detection rather than true absence. It also notes that murine typhus and scrub typhus are historically endemic yet rarely diagnosed, which implies that many infections may be misclassified as generic fever illnesses or attributed to other causes without laboratory confirmation.
This funding opportunity is positioned as a continuation and expansion of earlier CDC-supported work that began around 2011. That earlier effort helped establish a modern molecular diagnostic laboratory in Jakarta, deliver nationwide training in virology techniques and biosafety, and pilot a broader acute febrile illness surveillance network. The NOFO uses concrete prior successes to show what improved capacity can achieve: under the previous cooperative agreement (RFA-CK-15-001), partners reported the first identified cases of West Nile virus and Zika virus in Indonesia, conducted the first Zika seroprevalence study, and detected Rickettsia felis as a cause of fatal neurological disease for the first time. The implication is that better tools and systems do not just refine academic knowledge; they change what the health system is able to see and measure, which directly affects outbreak detection and clinical understanding.
From a broader policy standpoint, the opportunity is tied to Indonesia's role in the Global Health Security Agenda and to the country's Joint External Evaluation (JEE) priorities. The CDC frames the work as supporting national goals like strengthening the laboratory system and improving real-time surveillance for emerging pathogens. In other words, the project is not only about generating research findings; it is also about reinforcing core public health functions such as diagnostic readiness, biosafety practices, and surveillance performance in ways that align with internationally recognized preparedness benchmarks.
Administratively, this is a discretionary grant using a cooperative agreement mechanism, meaning CDC expects active involvement and close collaboration during the project rather than a hands-off funding relationship. The program sits under the health funding category and is associated with CFDA 93.084. The NOFO anticipated a single award, with an award ceiling of $1,000,000. It was posted in October 2019 with applications originally due in January 2020 (electronically submitted applications due by 5:00 p.m. ET on the deadline). Eligibility is listed broadly as "Others" with additional eligibility details referenced in the full announcement, suggesting it may be targeted toward specific institutions or partnership structures capable of carrying out advanced laboratory and surveillance work in Indonesia.
Overall, the opportunity is designed to push Indonesia's detection and characterization capabilities further so that emerging vector-borne and zoonotic threats are identified faster, confirmed more accurately, and understood well enough to guide public health action. It treats laboratory strengthening, workforce training, and surveillance expansion as mutually reinforcing pieces of a single goal: reducing the risk that a novel or under-recognized pathogen circulates quietly until it becomes a larger epidemic.Apply for RFA CK 20 002
- The Department of Health and Human Services, Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Detection and Characterization of Emerging Vector-Borne and Zoonotic Pathogens in Indonesia" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.084.
- This funding opportunity was created on Oct 19, 2019.
- Applicants must submit their applications by Jan 14, 2020 Electronically submitted applications must be submitted no later than 500 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Detection and Characterization of Emerging Vector-Borne and Zoonotic Pathogens in Indonesia (RFA CK 20 002)
What is the purpose of this grant opportunity?
The opportunity supports work to strengthen Indonesia's ability to rapidly detect, correctly identify, and better characterize emerging diseases that are either vector-borne (spread by mosquitoes, ticks, fleas, and other arthropods) or zoonotic (spreading from animals to humans). The intent is practical public health impact: improving the systems that help identify the cause of unusual febrile illness or suspected outbreaks quickly enough to guide timely response.
What is the official title and funding opportunity number?
The title is "Detection and Characterization of Emerging Vector-Borne and Zoonotic Pathogens in Indonesia." The Funding Opportunity Number is RFA CK 20 002.
Which agency is leading this opportunity?
This is a CDC-led cooperative agreement.
What funding mechanism is used?
The grant uses a cooperative agreement mechanism, which indicates CDC expects active involvement and close collaboration during the project rather than a hands-off funding relationship.
Is this a new program or a continuation of prior work?
It is positioned as a continuation and expansion of earlier CDC-supported work that began around 2011. The NOFO emphasizes building directly on laboratory capacity, surveillance systems, and scientific partnerships already established under earlier awards, rather than starting from scratch.
Why is Indonesia a focus for this work?
Indonesia is described as having an unusually high risk profile for emerging infectious diseases. Key drivers noted include its very large population, nearly 1,000 inhabited islands, wide equatorial geographic span, and constant movement of people, animals, and goods across diverse ecological zones. These factors can increase the chances that a pathogen emerges and spreads before being recognized, especially when early illness looks like common acute febrile disease.
Which pathogens or pathogen groups are highlighted as priorities?
The NOFO highlights two priority groups: arboviruses and Rickettsia. Arboviruses are transmitted by arthropods and can move between wildlife, livestock, and humans. Rickettsial diseases (including typhus group and spotted fever group illnesses) are also emphasized because they can be severe yet easily missed clinically without targeted diagnostics.
Why are arboviruses emphasized in this opportunity?
The NOFO points to a knowledge gap: relatively few pathogenic arboviruses have been documented in Indonesia compared with neighboring Australia. This is framed as likely under-detection rather than true absence, implying that stronger diagnostics and surveillance could reveal additional circulating arboviruses and improve outbreak recognition.
Why are rickettsial diseases emphasized in this opportunity?
Rickettsial diseases are emphasized because they can cause severe illness but are often missed clinically and require specific diagnostic testing. The NOFO notes that murine typhus and scrub typhus are historically endemic yet rarely diagnosed, suggesting many cases may be misclassified as generic febrile illness or attributed to other causes without laboratory confirmation.
What kinds of public health problems is the project trying to solve?
The project targets gaps in diagnostic coverage and surveillance that can allow outbreaks to grow unnoticed. It focuses on strengthening the ability to determine which pathogen is responsible when unusual febrile illness clusters or suspected outbreaks occur, supporting earlier detection and more effective response.
What types of capacity does the NOFO emphasize strengthening?
The opportunity frames laboratory strengthening, workforce training, and surveillance expansion as mutually reinforcing. It specifically references building on molecular diagnostic laboratory capacity, improving biosafety practices, expanding or improving surveillance performance, and supporting scientific partnerships to improve real-time detection and characterization of emerging threats.
What prior infrastructure or activities does this opportunity build on?
Earlier CDC-supported efforts described in the NOFO include establishing a modern molecular diagnostic laboratory in Jakarta, delivering nationwide training in virology techniques and biosafety, and piloting a broader acute febrile illness surveillance network.
What are examples of outcomes from earlier CDC-supported work mentioned in the NOFO?
The NOFO cites concrete prior successes under a previous cooperative agreement (RFA-CK-15-001), including reporting the first identified cases of West Nile virus and Zika virus in Indonesia, conducting the first Zika seroprevalence study, and detecting Rickettsia felis as a cause of fatal neurological disease for the first time.
How does this opportunity connect to broader national or international preparedness priorities?
The NOFO ties the work to Indonesia's role in the Global Health Security Agenda and to Joint External Evaluation (JEE) priorities. It frames the project as supporting national goals such as strengthening laboratory systems and improving real-time surveillance for emerging pathogens, aligned with recognized preparedness benchmarks.
What is the anticipated number of awards?
The NOFO anticipated a single award.
What is the award ceiling?
The award ceiling is $1,000,000.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.084.
What is the funding category?
The program sits under the health funding category.
When was the opportunity posted and when were applications due?
The NOFO was posted in October 2019. Applications were originally due in January 2020, with electronically submitted applications due by 5:00 p.m. ET on the deadline.
Who is eligible to apply?
Eligibility is listed broadly as "Others," with additional eligibility details referenced in the full announcement. This suggests the opportunity may be intended for specific institutions or partnership structures capable of conducting advanced laboratory and surveillance work in Indonesia.
Is this opportunity primarily research-focused or public health operations-focused?
Based on the description, the emphasis is on real-time public health impact rather than research alone. The NOFO highlights that improved tools and systems change what the health system can detect and measure, supporting outbreak detection, diagnostic readiness, biosafety, and surveillance performance alongside scientific characterization of pathogens.
What does "detection and characterization" mean in the context of this NOFO?
In the context provided, it refers to rapidly recognizing that an emerging vector-borne or zoonotic pathogen is causing illness, confirming the pathogen accurately using reliable diagnostics, and improving understanding of the pathogen in ways that help guide public health action when unusual febrile illnesses or outbreaks are suspected.
Browse more opportunities from the same category: Health
Next opportunity: A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trials Optional)
Previous opportunity: Head Start and/or Early Head Start Grantee -- Tarrant County, Texas
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CK 20 002
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CK 20 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Recovery Community Services Program Apply for TI 20 002 Funding Number: TI 20 002 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $300,000 |
| National Child Traumatic Stress Initiative – Category II Apply for SM 20 004 Funding Number: SM 20 004 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
| National Child Traumatic Stress Initiative – Category III - Community Treatment and Service (CTS) Centers Apply for SM 20 005 Funding Number: SM 20 005 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $4,200,000 |
| A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trials Optional) Apply for RFA AG 20 026 Funding Number: RFA AG 20 026 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Modeling Infectious Diseases in Healthcare Research Projects to Improve Prevention Research and Healthcare Delivery (MInD Healthcare) Apply for RFA CK 20 003 Funding Number: RFA CK 20 003 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $650,000 |
| Increasing Organ Donation Awareness Program Apply for HRSA 20 062 Funding Number: HRSA 20 062 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Enhancing Public Health Laboratory Capabilities and Increasing Capacity Apply for CDC RFA OE20 2001 Funding Number: CDC RFA OE20 2001 Agency: Department of Health and Human Services, Centers for Disease Control - CSELS Category: Health Funding Amount: $100,000,000 |
| The Substance Abuse and HIV Prevention Navigator Program for Racial/Ethnic Minorities Ages 13-24 Apply for SP 20 001 Funding Number: SP 20 001 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $200,000 |
| Rapid-Cycle Survey Collaborative for Patient and Provider Input on Immunization Issues Apply for RFA IP 20 005 Funding Number: RFA IP 20 005 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| USAID/Uganda Local Service Delivery for HIV/AIDS Activity Apply for 72061720RFA000002 Funding Number: 72061720RFA000002 Agency: Agency for International Development, Uganda USAID-Kampala Category: Health Funding Amount: $50,000,000 |
| Emergency Medical Services for Children Innovation and Improvement Center Apply for HRSA 20 037 Funding Number: HRSA 20 037 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $2,500,000 |
| Medical Monitoring Project (MMP) Apply for CDC RFA PS20 2005 Funding Number: CDC RFA PS20 2005 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| National Asian Language Tobacco Use and Dependence Treatment Support System Apply for CDC RFA DP20 2006 Funding Number: CDC RFA DP20 2006 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $700,000 |
| Leveraging a Data to Care Approach to Cure Hepatitis C within the Ryan White HIV/AIDS Program (RWHAP) Apply for HRSA 20 077 Funding Number: HRSA 20 077 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $1,000,000 |
| Assessing the Burden of Diabetes By Type in Children, Adolescents and Young Adults (DiCAYA) Apply for RFA DP 20 001 Funding Number: RFA DP 20 001 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 20 003 Funding Number: RFA CE 20 003 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $350,000 |
| Postdoctoral Training in General, Pediatric, and Public Health Dentistry Apply for HRSA 20 005 Funding Number: HRSA 20 005 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $650,000 |
| Nurse Faculty Loan Program (NFLP) Apply for HRSA 20 004 Funding Number: HRSA 20 004 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| AIDS Education and Training Center National Clinician Consultation Center Apply for HRSA 20 072 Funding Number: HRSA 20 072 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $2,700,000 |
| Rapid Antiretroviral Therapy (ART) Start in the Ryan White HIV/AIDS Program – Dissemination Assistance Provider Apply for HRSA 20 076 Funding Number: HRSA 20 076 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CK 20 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.